Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Clarify Pharma PLC - London-based investor in psychedelics companies - Acquires shares valued at £250,000 in both Atai Life Sciences Inc and Compass Pathways PLC as part of investment strategy.
Says Atai Life Sciences is a biotech company specialising in psychedelic-based drugs. Atai’s pipeline features nine programs, four of which are in the clinical testing stage. Atai’s Perception Neuroscience unit partnered with Otsuka, the Japanese drugmaker, to develop R-ketamine in treating depression. This was first major collaboration between a psychedelic-focused biotech firm and a big pharmaceutical company, the company says.
Compass Pathways PLC was founded in 2015 to support the research and development of psilocybin therapy which combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support for the treatment of mental health challenges.
Executive Chair Jonathan Bixby says: ‘I am delighted to announce Clarify Pharma’s purchase of shares in two trailblazing companies which are conducting pioneering research into psychedelic-assisted therapeutic treatment.’
Current stock price: 1.03p
12-month change: down from 2.45p
Copyright 2022 Alliance News Limited. All Rights Reserved.